108 related articles for article (PubMed ID: 2786740)
1. Immunoregulation of murine plasmacytoma. II. Target selectivity of anomalous killer cells and role of immune T cells for the induction.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):27-38. PubMed ID: 2786740
[TBL] [Abstract][Full Text] [Related]
2. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
[TBL] [Abstract][Full Text] [Related]
3. Host response to myeloma: I. Induction of cytotoxic and suppressor T cells by in vivo immunization with MOPC 104E plasmacytoma.
Miura T; Ghanta VK; Hiramoto RN
Cancer Invest; 1988; 6(1):29-37. PubMed ID: 2966651
[TBL] [Abstract][Full Text] [Related]
4. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
Miura T; Ghanta VK; Hiramoto RN
Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
[TBL] [Abstract][Full Text] [Related]
5. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
Wang KC; Berczi I; Sehon AH
Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
[TBL] [Abstract][Full Text] [Related]
6. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
7. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
Shrestha K; Hiramoto RN; Ghanta VK
Int J Cancer; 1984 Jun; 33(6):845-50. PubMed ID: 6610653
[TBL] [Abstract][Full Text] [Related]
8. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
9. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression.
Wang WC; Berczi I; Hoffmann EG; Sehon AH
Int J Cancer; 1980 Apr; 25(4):493-501. PubMed ID: 6246008
[TBL] [Abstract][Full Text] [Related]
10. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
Wise JA; Mokyr MB; Dray S
Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
[TBL] [Abstract][Full Text] [Related]
13. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
14. Lack of specificity for viral and H-2 antigens by anomalous T killer cells generated in murine leukocyte cultures.
Shain B; Holt CA; Lilly F
J Immunol; 1982 Aug; 129(2):722-9. PubMed ID: 6177779
[TBL] [Abstract][Full Text] [Related]
15. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
16. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
17. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
Marsili MA; Walker MC; Phillips-Quagliata JM
Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
[TBL] [Abstract][Full Text] [Related]
18. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
Brunda MJ; Taramelli D; Holden HT; Varesio L
J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
[TBL] [Abstract][Full Text] [Related]
19. Mannose-sensitivity and cross-reactivity with YAC-1 cells of cytotoxic T cells against syngeneic tumor cells.
Nakano K; Masuda T
Gan; 1983 Aug; 74(4):554-67. PubMed ID: 6605268
[TBL] [Abstract][Full Text] [Related]
20. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
Braun DP; Mokyr MB; Dray S
Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
